Advertisement

Therapeutic Angiogenesis

  • Editors
  • J. A. Dormandy
  • W. P. Dole
  • G. M. Rubanyi
Conference proceedings

Part of the Ernst Schering Research Foundation Workshop 28 book series (SCHERING FOUND, volume 28)

Table of contents

  1. Front Matter
    Pages I-XI
  2. K. S. Riddelle-Spencer, D. A. Cheresh
    Pages 23-39
  3. E. Deindl, W. Schaper
    Pages 67-86
  4. O. Hudlická, M. D. Brown
    Pages 87-123
  5. S. F. Aranki, F. Mannting, S. K. Shernan, N. C. Cummings, S. P. Sears, L. H. Cohn
    Pages 163-173
  6. Back Matter
    Pages 183-186

About these proceedings

Introduction

Over the past decade, rapid progress had been made in elucidating the cellular and molecular mechanisms of new blood vessel formation in both health and disease. Lack of sufficient angiogenesis (new capillary development) and collateral formation (remodeling of existing blood vessels) in adult tissues (e. g. , heart, brain, skeletal muscle) during criti­ cal ischemia has prompted novel therapeutic strategies to stimulate/fa­ cilitate angiogenesis and collateral formation in ischemic conditions ("therapeutic angiogenesis"). Therapeutic angiogenesis describes a strategy of inducing new col­ lateral vessels that can bypass vascular obstructions caused by atherosclerotic disease and stimulating new capillaries that can en­ hance tissue oxygen exchange. Naturally occurring growth factors (e. g. , FGFs, VEGFs) have been identified and demonstrated to induce new blood vessel formation in the adult organism. The therapeutic ap­ plication of these growth factors has been demonstrated to enhance these natural processes and have been shown in a number of animal models to increase blood flow and oxygen exchange to ischemic tis­ sues. Therapeutic angiogenesis therefore represents a new medical principle that is anticipated to be used as an adjunct or alternative to angioplasty and/or bypass surgery. A number of strategies have been proposed and tested to deliver growth factors. One strategy is the direct administration of the growth factor protein by intramuscular, intraarte­ rial or intravenous delivery.

Keywords

Angiogenic Growth Factors Protein Therapy Transmyocardial Laser angiogenesis artery cardiovascular coronary artery disease coronary heart disease gene therapy heart

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-662-03776-8
  • Copyright Information Springer-Verlag Berlin Heidelberg 1999
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-662-03778-2
  • Online ISBN 978-3-662-03776-8
  • Series Print ISSN 0947-6075
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology
Internal Medicine & Dermatology